Moderna rises after US FDA nod for next-gen COVID-19 vaccine

Moderna MRNA.O rises 5% to $27.86 premarket

Vaccine maker said U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE, for everyone aged 65 and older

Added mNEXSPIKE also approved for people aged 12-64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention

Noted vaccine expected to be available for the 2025-2026 respiratory virus season

Jefferies says FDA approval "incremental positive" for co as it shows regulator "still reasonable" in approving drugs with good data efficacy, packages

However, expects lower vaccination rates due to "vaccine fatigue and lower public interest in general"

MRNA sheds 36% this year, as of last close